Season 4 - Ep2: Extended interview on Lp(a) and aortic valve stenosis

10 snips

Feb 5, 2026

Borge Nordestgaard, a clinician-researcher from Copenhagen University Hospital known for his work on lipoprotein(a), discusses prevalence and strong genetic control of Lp(a). He explains Lp(a) biology, evidence linking it to calcific aortic valve stenosis, screening recommendations, current management strategies, and an ongoing trial testing major Lp(a) lowering to slow valve progression.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Lp(a) Is Mostly Genetic

Lp(a) levels are overwhelmingly genetic and largely immutable by lifestyle.
Borge Nordestgaard states more than 90% of Lp(a) determination comes from your parents.

INSIGHT

Lp(a) Acts Differently Than LDL

Lp(a) carries an apolipoprotein(a) that makes its disease mechanisms different from LDL.
Nordestgaard suggests Lp(a) may promote thrombosis rather than classic atherosclerosis.

INSIGHT

Strong Causality Between Lp(a) And Aortic Stenosis

Genetic and observational studies provide strong evidence that high Lp(a) causes aortic valve stenosis.
Nordestgaard emphasises minimal confounding because Lp(a) is genetically determined.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Host: Emer Joyce

Guest: Borge Nordestgaard

Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview

Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548

Disclaimer:

ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

All declarations of interest are listed at the end of the episode.

The ESC is not liable for any translated content of this video. The English language always prevails.

Declarations of interests:

Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.